In wake of biopharma mega buyouts, FTC kicks off review of industry’s dealmaking
Bristol Myers Squibb and Celgene. AbbVie and Allergan. Pfizer’s Upjohn unit and generics giant Mylan. These are three of the biggest pharma mergers of the past couple years. They’re also the kind of deals the Biden administration’s Federal Trade Commission (FTC) might have scrutinized more closely, an agency official said Tuesday in announcing a sweeping review… Read More »